← Curriculum & schedule

Day 3 · Wed · Jun 24 · Critique

Evaluation & Study Design

Data → a credible way to know whether a solution works.

AM lecture: Shalmali Joshi (Columbia) PM lecture: Olawale Salaudeen (MIT)

About this day

Before you build anything, you need to know what would count as evidence that it worked. The morning lecture covers study design and evaluation: estimands, utility-aligned metrics versus metrics of convenience, statistical power, fairness, and the threats to a study’s validity. The afternoon lecture brings the sharp empirical case that aggregate metrics routinely hide subgroup failures. The mode is critique — you learn to take an evaluation apart before you trust it.

Schedule

TimeBlock
9:00–9:15Morning handoff
9:15–10:30AM lecture (Joshi)
10:30–11:00Coffee
11:00–12:30Small Group 1
12:30–1:30Lunch
1:30–2:45PM lecture (Salaudeen)
2:45–4:15Workshop — build your project’s evaluation notebook
4:15–5:45Small Group 2 (closing)
5:45–6:00Daily wrap — recap & look ahead
6:00Dinner

Morning lecture outline

Evaluation & study design: how would you know if it worked? A working outline of the lecture’s content.

  • The question of the day. Evaluating whether an AI system (the model plus the ecosystem around it) works as intended — the validation and study-design choices, not post-deployment monitoring.
  • Precursors: threats to validity. Assume construct validity and no leakage — then see why that’s hard, with real leakage cases (antihypertensives “predicting” hypertension; antibiotics “predicting” sepsis).
  • Distribution shift. Covariate (X) vs. concept (Y∣X) shift; “accuracy on the line” and when it holds; attributing a performance drop to a specific shift.
  • Case study — the Epic Sepsis Model. A label-definition mismatch and feature leakage that broke external validity, worst in the sickest patients.
  • Shortcut learning. Models that latch onto the scanner, not the pathology (COVID chest X-ray) — and why a same-distribution holdout hides it.
  • Anatomy of an estimand. Population, data, outcome/label, timing/horizon, operating point, how the score is used, and the primary endpoint.
  • In-silico metrics. Discrimination (AUROC/AUPRC under class imbalance), calibration (reliability, subgroup/multicalibration), and decision-curve analysis / net benefit — what each does and does not tell you.
  • Evaluation is causal. Predictions made to drive decisions need p(y∣x, do(t)), not p(y∣x, t); identifiability, self-fulfilling prophecies, and why a working intervention can lower AUROC.
  • Subgroups & fairness. Aggregate metrics hide subgroup failure; when — and whether — to be subgroup/race-aware.
  • Stages of evaluation. In silico → silent → pilot → prospective trial: target vs. deployment population, the silent trial, and RCTs with AI as the intervention (cluster designs, contamination, DECIDE-AI / CONSORT-AI).
  • Deployed tools and generative systems. Retrospective panel analyses; and evaluation without ground truth — selective prediction and the pitfalls of LLM-as-judge.

What you’ll be able to do

  • Define an estimand and utility-aligned metrics for your project.
  • Design a subgroup / fairness evaluation.
  • Name the top threats to your study’s internal validity.

Small group & workshop

In Small Group 1, the group works through the Day 3 Workbook prompt — what success and failure look like for each project, the metrics that capture both, and how you’d measure them. See how the small groups run.

The workshop then has you build an evaluation notebook for your own project — discrimination, calibration, clinical utility, subgroup disaggregation, power, and leakage/shortcut probing. You start from a blank notebook (no template); use an AI coding assistant to scaffold a synthetic stand-in for your project if you like.

The closing small group ends with each person noting how their evaluation thinking moved over the day.

Project Workbook — Part 3: Evaluation

How you’d know you succeeded and how you’d know you failed; the set of metrics that captures both (the frontier your solution should push); how you’d measure them in deployment and approximate them retrospectively, and the errors that introduces; and the problem-specific confounders that could invalidate your evaluation.

Additional resources

Suggested readings

  1. Wong et al. (2021), External validation of a widely implemented proprietary sepsis prediction model. JAMA Internal Medicine.
  2. DeGrave, Janizek & Lee (2021), AI for radiographic COVID-19 detection selects shortcuts over signal. Nature Machine Intelligence.
  3. McDermott et al. (2024), A Closer Look at AUROC and AUPRC under Class Imbalance. NeurIPS.
  4. Joshi et al. (2025), AI as an Intervention: improving clinical outcomes relies on a causal approach to AI development and validation. JAMIA.
  5. van Amsterdam et al. (2025), When Accurate Prediction Models Yield Harmful Self-Fulfilling Prophecies. Patterns.
  6. Miller et al. (2021), Accuracy on the Line: on the strong correlation between OOD and in-distribution generalization. ICML.
  7. Coots, Saghafian, Kent & Goel (2025), A Framework for Considering the Value of Race and Ethnicity in Estimating Disease Risk. Annals of Internal Medicine.
  8. Kwong et al. (2022), The Silent Trial — the bridge between bench-to-bedside clinical AI. Frontiers in Digital Health.
  9. Salaudeen et al. (2025), Measurement to Meaning: a validity-centered framework for AI evaluation.
  10. Vickers & Elkin (2006), Decision Curve Analysis: a novel method for evaluating prediction models. Medical Decision Making.
  11. Verma et al. (2024), Clinical evaluation of a machine learning–based early warning system for patient deterioration (CHARTwatch). CMAJ.